NeOnc Launches $15M At-Market Offering, Seeks FDA Meeting for NEO100
NTHI sits 20% above its 52-week low of $3.005.
Summary
NeOnc Technologies announced a $15 million registered direct offering priced at-the-market, adding to its existing $75M ATM program and $300M shelf. The company also plans to request a Type B FDA meeting for NEO100's registrational pathway, a step toward potential approval. With only $2.0M in cash as of Q2 and a going concern warning, this raise is critical for funding operations and clinical trials. The offering is dilutive at current prices, but the FDA meeting request signals progress on the lead asset. Investors should watch for the FDA meeting outcome and further capital raises.
At the time of this announcement, NTHI was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.4M. The 52-week trading range was $3.01 to $12.99. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.